查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球膀胱癌市场评估：按类型、方式、最终用户、地区、机会、预测（2017-2031）
市场调查报告书
商品编码
1417600

全球膀胱癌市场评估：按类型、方式、最终用户、地区、机会、预测（2017-2031）

Bladder Cancer Market Assessment, By Types, By Modality, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 225 Pages | 商品交期: 3-5个工作天内

价格

全球膀胱癌市场规模预计到2023年将达到45.1亿美元，到2031年将达到68.1亿美元，2024-2031年预测期间复合年增长率为5.28%。众多原因正在推动全球膀胱癌市场的发展，包括膀胱癌盛行率的增加、老年人口的增加、诊断和治疗技术的进步、政府措施以及研发资金的增加。膀胱癌盛行率的增加是全球膀胱癌市场的主要驱动因素。

膀胱癌是全球第十大常见癌症。这可能是由于多种因素造成的，包括人口老化和环境致癌物暴露的增加。随着世界人口老化，膀胱癌的风险增加，增加了对诊断和治疗方案的需求。医疗基础设施的进步和可近性的提高正在促进全球膀胱癌市场的成长。更好地获得医疗服务、更高品质的护理和先进的设施可以使膀胱癌患者更早发现并获得更好的结果。

影像技术、非侵入性尿液检测和分子诊断方面的创新正在彻底改变早期检测和监测，从而改善患者的治疗结果。烟草消费和接触工业化学品的增加在膀胱癌的发展中发挥重要作用，迅速增加了全球膀胱癌市场的需求。市场正在见证可提高治疗效果并增强患者体验的技术进步，包括微创手术技术、机器人辅助手术和精准医疗。政府措施和研究资金正在促进市场扩张。膀胱癌研究（包括临床试验和药物开发）的投资增加正在推动创新并带来新的治疗方法和诊断工具。

膀胱癌盛行率增加

膀胱癌发生率和盛行率的增加在扩大全球膀胱癌市场方面发挥重要作用。膀胱癌是世界上第六大常见癌症，有明显的性别差异，在男性中排名第十，在女性中排名第十七。这种高盛行率是由许多因素造成的，包括老化、接触环境致癌物的增加以及个人生活方式的选择。随着膀胱癌患者数量持续增加，对先进诊断技术、治疗和医疗照护的需求不断增加。需求的激增推动了膀胱癌市场的研究、创新和投资，以实现早期检测、更先进的治疗和加强患者护理。

技术进步

最近的技术进步对于全球膀胱癌市场的发展至关重要。这些医疗创新彻底改变了膀胱癌的诊断、治疗和监测方式。这些创新包括微创手术技术的发展、引入机器人辅助手术以提高精确度以及引入个人化医疗方法。这些突破透过减少侵入性和加速康復来提高治疗效果和整体患者体验。此外，最先进的影像方式和诊断工具有助于早期检测，是改善膀胱癌预后的关键因素。这些技术进步处于塑造全球膀胱癌市场成长和前景的最前沿。

政府的努力

世界各国政府积极参与各种举措，包括与各种组织建立伙伴关係，以提高对膀胱癌的认识。这些努力包括开展公共卫生运动、实施教育计画和支持研究工作。透过优先提高意识，政府和合作组织旨在教育大众了解膀胱癌的风险因素、症状、早期检测和可用于治疗的资源。这提高了我们对这种疾病的了解，并激励我们采取预防措施并及时就医。提高意识最终将导致早期诊断、改善治疗结果并减轻医疗保健系统的负担，凸显了这项全球努力对抗膀胱癌的重要性。

本报告研究和分析了全球膀胱癌市场，提供市场规模和预测、市场动态、主要参与者趋势和前景等。

目录

第一章研究方法论

第二章 专案范围与定义

第三章执行摘要

第四章全球膀胱癌市场展望（2017-2031）

  • 市场规模及预测
    • 金钱数额
    • 数量
  • 按类型
    • 尿路上皮癌
    • 腺癌
    • 鳞状细胞癌
    • 其他
  • 按方式
    • 诊断
    • 治疗
  • 按最终用户
    • 医院
    • 门诊手术中心
    • 专科诊所
    • 药店
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 南美洲
    • 亚太地区
    • 中东/非洲
  • 市场占有率：依公司划分（2023 年）

第五章全球膀胱癌市场展望：按地区（2017-2031）

  • 北美
    • 市场规模及预测
    • 按类型
    • 按方式
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第六章 市场测绘（2023）

  • 按类型
  • 按方式
  • 按最终用户
  • 按地区

第七章 宏观环境与产业结构

  • 供需分析
  • 进出口分析
  • 价值链分析
  • PESTEL 分析
  • 波特五力分析

第八章市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第九章 监理架构与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/新技术

第十章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT分析（5家进入市场的公司）
  • 专利分析（如果适用）

第11章价格分析

第十二章案例研究

第十三章 主要公司展望

  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Johnson & Johnson Innovative Medicine
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Ferring B.V.
  • Seagen Inc.
  • Asieris Pharmaceuticals
  • Bristol-Myers Squibb Company

第十四章 战略建议

第十五章 关于我们公司、免责声明

Product Code: MX10894

Global bladder cancer market size was valued at USD 4.51 billion in 2023, which is expected to reach USD 6.81 billion in 2031, with a CAGR of 5.28% for the forecast period between 2024 and 2031. Numerous factors are propelling the global bladder cancer market, such as the increasing prevalence of bladder cancer, the growing geriatric population, technological advancements in diagnostic and treatment methodologies, government initiatives, and increasing funding for research and development. The rising prevalence of bladder cancer is a significant factor driving the global bladder cancer market.

Bladder cancer ranks as the 10th most common cancer worldwide. It can be attributed to various factors, including an aging population and increased exposure to environmental carcinogens. As the global population ages, the risk of bladder cancer increases, creating a growing demand for diagnostic and treatment options. Advancements in healthcare infrastructure and growing accessibility are contributing to the growth of global bladder cancer market. Better access to healthcare services, higher quality of care, and advanced facilities can lead to early detection and better outcomes for bladder cancer patients.

Innovations in imaging technologies, non-invasive urine tests, and molecular diagnostics have revolutionized early detection and monitoring, leading to better patient outcomes. Increasing consumption of tobacco and increased exposure to industrial chemicals play a significant role in bladder cancer development, surging the demand for the global bladder cancer market. The market is witnessing technological advancements such as minimally invasive surgical techniques, robotic-assisted surgery, and precision medicine which improves the effectiveness of treatments and enhance patient experiences. Government initiatives and research funding are contributing to market expansion. Growing investment in bladder cancer research, including clinical trials and drug development, is expediting innovation and introducing new therapies and diagnostic tools.

Rising Prevalence of Bladder Cancer

The increasing incidence and prevalence of bladder cancer play a significant role in the expansion of the global bladder cancer market. Bladder cancer, recognized as the 6th most widespread form of cancer worldwide, presents a distinct gender divide, with it being the 10th most common cancer among men and the 17th most prevalent among women. The high prevalence is shaped by a multitude of factors, including the aging population, heightened exposure to environmental carcinogens, and individual lifestyle choices. As the number of bladder cancer cases continues to rise, there is an increasing demand for advanced diagnostic techniques, treatment modalities, and healthcare provisions. The surge in demand stimulates research, fosters innovation, and attracts investments in the bladder cancer market, geared towards enhancing early detection, more advanced therapies, and increased patient care.

Technological Advancements

Recent technological advancements are pivotal in driving the global bladder cancer market forward. These medical technology innovations have revolutionized how bladder cancer is diagnosed, treated, and monitored. They encompass the creation of less invasive surgical techniques, the incorporation of precision-enhancing robotic-assisted surgery, and the introduction of personalized medicine approaches. These breakthroughs enhance treatments' efficacy and the overall patient experience by reducing invasiveness and speeding up recovery. Additionally, state-of-the-art imaging methods and diagnostic tools are facilitating early detection, which is a critical factor in enhancing bladder cancer outcomes. These technological advancements are at the forefront of shaping the growth and potential of the global bladder cancer market. UC San Diego Health became the first healthcare system to provide a new technology that uses white light, blue light, and an imaging dye that causes cancer cells to glow fluorescent pink to identify and monitor bladder cancer in both clinic and operating room settings in San Diego.

Government Initiatives

Governments around the globe are actively involved in various initiatives such as partnerships with various organizations to increase awareness about bladder cancer. These initiatives encompass the deployment of public health campaigns, the implementation of educational programs, and the provision of support for research endeavors. By prioritizing awareness, governments and collaborating organizations aim to educate the public about risk factors, symptoms, early detection, and the available resources for managing bladder cancer. It fosters a deeper understanding of the disease and motivates individuals to embrace preventive measures and seek prompt medical attention. Enhanced awareness can ultimately result in earlier diagnoses, improved treatment outcomes, and a decreased burden on healthcare systems, underscoring the significance of these global initiatives in the battle against bladder cancer.

Fight Bladder Cancer UK, a proactive national organization driven by patients, hosted a parliamentary event in May 2023. Fight Bladder Cancer places a strong emphasis on the significance of timely screening, urging people to remain vigilant regarding possible symptoms and promptly consult a healthcare professional. It involves raising awareness among healthcare practitioners about identifying early indicators and implementing effective diagnostic procedures.

Transitional Cell Carcinoma Dominated the Market

The global bladder cancer market is witnessing a surging need for treatments custom-tailored for transitional cell carcinoma (TCC). This type of bladder cancer comprises a substantial share of all bladder cancer cases. The growing demand can be ascribed to multiple factors, including the rising incidence of transitional cell carcinoma, advancements in diagnostic techniques enabling more precise TCC detection, and an increased emphasis on individualized treatment strategies. As awareness and comprehension of the distinctive attributes and treatment requisites of TCC broaden, pharmaceutical companies and healthcare providers are allocating resources to research and therapies that address the specific needs of this subset of bladder cancer patients.

In April 2023, the Japanese multinational pharmaceutical company Astellas Pharma disclosed that Food and Drug Administration (FDA) had issued accelerated approval for Padcev (enfortumab vedotin-ejfv) in combination with Keytruda (pembrolizumab) for the initial treatment of adults with locally advanced or metastatic transitional cell carcinoma who are not suitable candidates for cisplatin-containing chemotherapy.

Future Market Scenario

The outlook for the global bladder cancer market appears highly promising, owing to its exceptional opportunities. Bladder cancer ranks amongst the most prevalent cancers globally, rendering it a central focus for pharmaceutical and biotechnology firms. The increasing incidence of bladder cancer, influenced by factors such as an aging population, environmental factors, and evolving lifestyles, fuels a rising demand for innovative diagnostic tools and therapeutic interventions.

Furthermore, significant technological advancements have reshaped the landscape such as introduction of new treatments, precision medicine, and less invasive surgical methods that enhance patient outcomes. Strategic alliances and acquisitions among major industry players further amplify the market's growth potential, which stimulates collaborative research and development endeavors. With an expanding awareness and comprehension of bladder cancer, the market is primed to make substantial strides in the pursuit of more efficacious treatments, early detection, and enhanced patient care.

Key Players Landscape and Outlook

In the global bladder cancer market, prominent pharmaceutical and biotechnology firms are progressively entering into strategic alliances to seize the extensive prospects. These partnerships allow these companies to merge their knowledge, resources, and research endeavors, with the goal of creating innovative diagnostic tools, therapies, and treatment solutions. Moreover, these collaborative efforts facilitate the exchange of expertise and cutting-edge technologies, which are vital in addressing the intricacies of bladder cancer. By consolidating their capabilities, these companies aspire to expedite the development of pharmaceuticals, improve patient care, and meet the unfulfilled medical requirements in the domain. Ultimately, these partnerships empower the industry to cater to the escalating demand more effectively for bladder cancer treatments and diagnostic methods.

In October 2023, the European Union approved the acquisition of the biotechnology company Seagen, which specializes in innovative cancer treatments by Pfizer. The deal, valued at USD 43 billion, is set to broaden Pfizer's range of bladder cancer medications through the incorporation of Seagen's therapies.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Bladder Cancer Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Types
    • 4.2.1. Urothelial Carcinoma
    • 4.2.2. Adenocarcinoma
    • 4.2.3. Squamous Cell Carcinoma
    • 4.2.4. Others
  • 4.3. By Modality
    • 4.3.1. Diagnosis
      • 4.3.1.1. Cytology
      • 4.3.1.2. Cystoscopy
      • 4.3.1.3. MRI Scan
      • 4.3.1.4. CT Scan
    • 4.3.2. Treatment
      • 4.3.2.1. Surgery
      • 4.3.2.2. Radiation Therapy
      • 4.3.2.3. Radiopharmaceuticals
      • 4.3.2.4. Transurethral Bladder Tumour Resection
      • 4.3.2.5. Chemotherapy
      • 4.3.2.6. Immunotherapy
      • 4.3.2.7. Gene Therapy
      • 4.3.2.8. Cryotherapy
      • 4.3.2.9. High-Intensity Focused Ultrasound
      • 4.3.2.10. Targeted Therapy
  • 4.4. By End-user
    • 4.4.1. Hospitals
    • 4.4.2. Ambulatory Surgical Centers
    • 4.4.3. Specialty Clinics
    • 4.4.4. Pharmacies
    • 4.4.5. Others
  • 4.5. By Region
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. South America
    • 4.5.4. Asia-Pacific
    • 4.5.5. Middle East and Africa
  • 4.6. By Company Market Share (%), 2023

5. Global Bladder Cancer Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Types
      • 5.1.2.1. Urothelial Carcinoma
      • 5.1.2.2. Adenocarcinoma
      • 5.1.2.3. Squamous Cell Carcinoma
      • 5.1.2.4. Others
    • 5.1.3. By Modality
      • 5.1.3.1. Diagnosis
      • 5.1.3.1.1. Cytology
      • 5.1.3.1.2. Cystoscopy
      • 5.1.3.1.3. MRI Scan
      • 5.1.3.1.4. CT Scan
      • 5.1.3.2. Treatment
      • 5.1.3.2.1. Surgery
      • 5.1.3.2.2. Radiation Therapy
      • 5.1.3.2.3. Radiopharmaceuticals
      • 5.1.3.2.4. Transurethral Bladder Tumour Resection
      • 5.1.3.2.5. Chemotherapy
      • 5.1.3.2.6. Immunotherapy
      • 5.1.3.2.7. Gene Therapy
      • 5.1.3.2.8. Cryotherapy
      • 5.1.3.2.9. High-Intensity Focused Ultrasound
      • 5.1.3.2.10. Targeted Therapy
    • 5.1.4. By End-user
      • 5.1.4.1. Hospitals
      • 5.1.4.2. Ambulatory Surgical Centers
      • 5.1.4.3. Specialty Clinics
      • 5.1.4.4. Pharmacies
      • 5.1.4.5. Others
    • 5.1.5. United States*
      • 5.1.5.1. Market Size and Forecast
      • 5.1.5.1.1. Value
      • 5.1.5.1.2. Volume
      • 5.1.5.2. By Types
      • 5.1.5.2.1. Urothelial Carcinoma
      • 5.1.5.2.2. Adenocarcinoma
      • 5.1.5.2.3. Squamous Cell Carcinoma
      • 5.1.5.2.4. Others
      • 5.1.5.3. By Modality
      • 5.1.5.3.1. Diagnosis
      • 5.1.5.3.1.1. Cytology
      • 5.1.5.3.1.2. Cystoscopy
      • 5.1.5.3.1.3. MRI Scan
      • 5.1.5.3.1.4. CT Scan
      • 5.1.5.3.2. Treatment
      • 5.1.5.3.2.1. Surgery
      • 5.1.5.3.2.2. Radiation Therapy
      • 5.1.5.3.2.3. Radiopharmaceuticals
      • 5.1.5.3.2.4. Transurethral Bladder Tumour Resection
      • 5.1.5.3.2.5. Chemotherapy
      • 5.1.5.3.2.6. Immunotherapy
      • 5.1.5.3.2.7. Gene Therapy
      • 5.1.5.3.2.8. Cryotherapy
      • 5.1.5.3.2.9. High-Intensity Focused Ultrasound
      • 5.1.5.3.2.10. Targeted Therapy
      • 5.1.5.4. By End-user
      • 5.1.5.4.1. Hospitals
      • 5.1.5.4.2. Ambulatory Surgical Centers
      • 5.1.5.4.3. Specialty Clinics
      • 5.1.5.4.4. Pharmacies
      • 5.1.5.4.5. Others
    • 5.1.6. Canada
    • 5.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Types
  • 6.2. By Modality
  • 6.3. By End-user
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Astellas Pharma Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. AstraZeneca plc
  • 13.3. Johnson & Johnson Innovative Medicine
  • 13.4. Bayer AG
  • 13.5. Merck & Co., Inc.
  • 13.6. Pfizer, Inc.
  • 13.7. Ferring B.V.
  • 13.8. Seagen Inc.
  • 13.9. Asieris Pharmaceuticals
  • 13.10. Bristol-Myers Squibb Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 4. Global Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 5. Global Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 6. Global Bladder Cancer Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 10. North America Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 11. North America Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 12. North America Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 16. United States Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 17. United States Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 18. Canada Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 21. Canada Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 22. Canada Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 23. Mexico Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 26. Mexico Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 27. Mexico Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 28. Europe Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 31. Europe Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 32. Europe Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 37. Germany Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 38. Germany Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 39. France Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 42. France Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 43. France Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 44. Italy Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 47. Italy Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 48. Italy Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 49. United Kingdom Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 52. United Kingdom Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 53. United Kingdom Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 54. Russia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 57. Russia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 58. Russia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 59. Netherlands Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 62. Netherlands Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 63. Netherlands Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 64. Spain Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 67. Spain Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 68. Spain Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 69. Turkey Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 72. Turkey Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 73. Turkey Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 74. Poland Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 77. Poland Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 78. Poland Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 79. South America Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 82. South America Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 83. South America Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 84. South America Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 88. Brazil Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 89. Brazil Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 90. Argentina Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 93. Argentina Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 94. Argentina Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 95. Asia-Pacific Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 98. Asia-Pacific Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 99. Asia-Pacific Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 100. Asia-Pacific Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 101. India Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 104. India Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 105. India Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 106. China Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 109. China Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 110. China Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 111. Japan Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 114. Japan Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 115. Japan Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 116. Australia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 119. Australia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 120. Australia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 121. Vietnam Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 124. Vietnam Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 125. Vietnam Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 126. South Korea Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 129. South Korea Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 130. South Korea Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 131. Indonesia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 134. Indonesia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 135. Indonesia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 136. Philippines Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 139. Philippines Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 140. Philippines Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 141. Middle East & Africa Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 144. Middle East & Africa Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 145. Middle East & Africa Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 146. Middle East & Africa Bladder Cancer Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 150. Saudi Arabia Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 151. Saudi Arabia Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 152. UAE Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 155. UAE Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 156. UAE Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 157. South Africa Bladder Cancer Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Bladder Cancer Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Bladder Cancer Market Share (%), By Types, 2017-2031F
  • Figure 160. South Africa Bladder Cancer Market Share (%), By Modality, 2017-2031F
  • Figure 161. South Africa Bladder Cancer Market Share (%), By End-user, 2017-2031F
  • Figure 162. By Types Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Modality Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023